Construction method of transgenic Angale mink model
Through the combination of CRISPR/Cas9 system and sgRNA, centrifugal treatment and cell microinjection technology, the problem of low gene knock-in efficiency in the ferret model in the existing technology is solved, and efficient and accurate gene knock-in is achieved, which is suitable for a variety of purposes. 生物医学研究。
Patent Information
- Application Number
- CN202411213302.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-30
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2044-08-30
AI Technical Summary
The existing gene knock-in ferret model methods are complex in operation and inefficient in efficiency, making it difficult to achieve efficient and accurate gene knock-in.
The CRISPR/Cas9 system was used to introduce sgRNA into the Angro ferret fertilized eggs through non-homologous recombination method, and combined with centrifugal treatment and cell microinjection technology to improve the efficiency and accuracy of gene knock-in.
The transgenic Angro ferret model of multiple strains has been successfully constructed, which has improved the efficiency and accuracy of gene knock-in, and is suitable for cerebral cortex development, autism research and the pathogenic mechanism of new coronavirus infection.
Smart Images

Figure BDA0005020819160000051 
Figure BDA0005020819160000061 
Figure BDA0005020819160000071
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology, and in particular to a method for constructing a transgenic Anglo ferret model. Further, the present invention relates to a transgenic Anglo ferret model and sgRNA. Background Art
[0002] In the field of biomedical research, ferrets, as a higher mammal, have gradually become an important experimental animal model due to their similar anatomical structure, metabolic pathways and physiological characteristics to human organs, as well as their sensitivity to a variety of human pathogens. In recent years, the ferret model has demonstrated its unique value in multiple research fields, including brain development, neurological function, spinal cord injury, epilepsy, heart disease, immune system function, obesity, oncology, and a variety of lung diseases including chronic obstructive pulmonary disease, lung cysts, pulmonary fibrosis, and lung cancer. In addition, the ferret model also plays a key role in infectious disease research.
[0003] With the rapid development of gene editing technology, especially the CRISPR / Cas9 system, the efficiency and accuracy of genome editing have been significantly improved, providing new improvements for the application of ferret models. However, the existing methods for gene knock-in ferret models are complicated and inefficient.
[0004] Therefore, it is urgent to develop a new method for preparing a highly efficient and accurate transgenic knock-in ferret model to improve the efficiency and accuracy of gene knock-in. Summary of the invention
[0005] The present invention aims to solve at least one of the technical problems existing in the prior art to a certain extent. To this end, the present invention provides a method for constructing a transgenic Anglo ferret model.
[0006] The present invention is accomplished based on the following findings of the inventors:
[0007] The existing technology mainly obtains transgenic Anglo ferret models through non-homologous recombination based on CRISPR / Cas9, which is complex to operate, inefficient, and difficult to knock in accurately. In order to overcome this problem, the inventors have developed a method for preparing an efficient and accurate transgenic knock-in Anglo ferret model, and have successfully prepared multiple strains of transgenic knock-in Anglo ferret strains.
[0008] In the first aspect of the present invention, the present invention proposes a method for constructing a transgenic Anglo ferret model. According to an embodiment of the present invention, the method includes: introducing sgRNA into an Anglo ferret fertilized egg to obtain a transgenic ferret model, and the sgRNA is suitable for targeting pre-intervention genes. According to the method of an embodiment of the present invention, a transgenic Anglo ferret model can be efficiently constructed, including gene knock-in, gene knockout and humanized ferret model.
[0009] According to an embodiment of the present invention, before the introduction, the method further includes: centrifuging the ferret fertilized eggs.
[0010] According to an embodiment of the present invention, the speed of the centrifugal treatment is 7800g-8000g.
[0011] According to an embodiment of the present invention, the centrifugal treatment time is 6 minutes to 8 minutes.
[0012] According to an embodiment of the present invention, the speed of the centrifugal treatment is 7850g-7950g.
[0013] According to an embodiment of the present invention, the centrifugal treatment time is 6.5 minutes to 7.5 minutes.
[0014] According to an embodiment of the present invention, the introduction of sgRNA into the fertilized egg of Anglo ferret is performed by at least one of the following methods: nuclear microinjection and cytoplasmic microinjection.
[0015] According to an embodiment of the present invention, after the centrifugation treatment, the cell nucleus microinjection is performed on the fertilized egg showing the nuclear region.
[0016] According to an embodiment of the present invention, after the centrifugation, the fertilized egg that does not show a nuclear region is subjected to the cytoplasmic microinjection.
[0017] According to an embodiment of the present invention, the cell nucleus microinjection pressure is 200Pa-240Pa.
[0018] According to an embodiment of the present invention, the cell nucleus microinjection time is 0.35 seconds to 0.45 seconds.
[0019] According to an embodiment of the present invention, the cytoplasmic microinjection pressure is 190Pa to 210Pa.
[0020] According to an embodiment of the present invention, the time of the cytoplasmic microinjection is 0.25 seconds to 0.35 seconds.
[0021] According to an embodiment of the present invention, the ferret fertilized egg is obtained by the following method:
[0022] HCG is injected into the body of a female mink after normal mating; and a fertilized egg is removed after a predetermined time of HCG injection to obtain the ferret fertilized egg; wherein the HCG is injected into the body of a female mink within 30 minutes to 1 hour after normal mating.
[0023] According to an embodiment of the present invention, the injection amount of HCG is 250 units to 350 units.
[0024] According to an embodiment of the present invention, the fertilized egg retrieval process is performed 42 to 44 hours after the HCG injection.
[0025] According to an embodiment of the present invention, the sgRNA is suitable for targeting at least one of Emx1, Nkx2.1, hAce2 and Chd8.
[0026] According to an embodiment of the present invention, the CrRNA of the sgRNA has at least one of the nucleotide sequences shown in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 44.
[0027] According to an embodiment of the present invention, the CrRNA of the sgRNA has a nucleotide sequence as shown in SEQ ID NO:1.
[0028] According to an embodiment of the present invention, the CrRNA of the sgRNA has a nucleotide sequence as shown in SEQ ID NO:2.
[0029] According to an embodiment of the present invention, the CrRNA of the sgRNA has a nucleotide sequence as shown in SEQ ID NO:3.
[0030] According to an embodiment of the present invention, the CrRNA of the sgRNA has a nucleotide sequence as shown in SEQ ID NO:44.
[0031] In a second aspect of the present invention, the present invention provides a transgenic Anglo ferret model. According to an embodiment of the present invention, the model is prepared using the method described in the first aspect of the present invention. The ferret model according to an embodiment of the present invention can be widely used in the study of cerebral cortex development and function, autism mechanism research, and the pathogenic mechanism of SARS-CoV-2 infection and vaccine drug development.
[0032] According to an embodiment of the present invention, the transgenic Anglo ferret model includes at least one of Emx1-CreERT2 transgenic Anglo ferret, Nkx2.1-CreERT2 transgenic Anglo ferret, humanized Ace2 replacement ferret model and Chd8 knockout transgenic Anglo ferret.
[0033] In the third aspect of the present invention, the present invention proposes an sgRNA. According to an embodiment of the present invention, the CrRNA of the sgRNA has at least one of the nucleotide sequences shown in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:44. According to an embodiment of the present invention, the CrRNA of the sgRNA has a nucleotide sequence as shown in SEQ ID NO:1. According to an embodiment of the present invention, the CrRNA of the sgRNA has a nucleotide sequence as shown in SEQ ID NO:2. According to an embodiment of the present invention, the CrRNA of the sgRNA has a nucleotide sequence as shown in SEQ ID NO:3. According to an embodiment of the present invention, the CrRNA of the sgRNA has a nucleotide sequence as shown in SEQ ID NO:44. According to an embodiment of the present invention, the trRNA of the sgRNA is suitable for targeting Cas9 protein. The sgRNA according to an embodiment of the present invention can accurately and efficiently target pre-intervention genes.
[0034] Additional aspects and advantages of the present invention will be given in part in the following description and in part will be obvious from the following description, or will be learned through practice of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0035] The above and / or additional aspects and advantages of the present invention will become apparent and easily understood from the description of the embodiments in conjunction with the following drawings, in which:
[0036] Figure 1 Schematic diagram of designing the Emx1-CreERT2 ferret model according to an embodiment of the present application.
[0037] Figure 2 This is a schematic diagram of the sequences before and after the sgRNA targeting site for the Emx1 gene designed according to an embodiment of the present application.
[0038] Figure 3 It is the in vitro cutting efficiency of the Emx1-CreERT2 model sgRNA according to the embodiment of the present application.
[0039] Figure 4 This is a donor plasmid map of the Emx1-CreERT2 model according to an embodiment of the present application.
[0040] Figure 5 The Emx1-CreERT2 model primer design and gene identification results according to the examples of the present application.
[0041] Figure 6 This is a result diagram of the gain and loss of both ends of the knock-in fragment of the Emx1-CreERT2 model according to the embodiment of the present application.
[0042] Figure 7 This is a specific analysis diagram of CreER cell expression in the Emx1-CreERT2 model according to an example of the present application.
[0043] Figure 8 Schematic diagram of designing the Nkx2.1-CreERT2 ferret model according to an embodiment of the present application.
[0044] Fig. 9 This is a schematic diagram of the before and after sequences of the sgRNA targeting site for the Nkx2.1 gene designed according to an embodiment of the present application.
[0045] Fig.10 : is the in vitro cutting efficiency of the Nkx2.1-CreERT2 model sgRNA according to the examples of the present application.
[0046] Fig.11 This is a donor plasmid map of the Nkx2.1-CreERT2 model according to an embodiment of the present application.
[0047] Fig.12 The figure shows the primer design and gene identification results of the Nkx2.1-CreERT2 model according to the embodiments of the present application.
[0048] Fig.13 This is a result diagram of the gain and loss of both ends of the knock-in fragment of the Nkx2.1-CreERT2 model according to an embodiment of the present application.
[0049] Fig.14 This is a diagram showing the verification results of the Nkx2.1-CreERT2 model immunoblotting experiment according to an embodiment of the present application.
[0050] Fig.15 Schematic diagram of designing the hAce2-tdTomato ferret model according to an embodiment of the present application.
[0051] Fig.16 This is a schematic diagram of the before and after sequences of the sgRNA targeting site for the hAce2 gene designed according to an embodiment of the present application.
[0052] Fig.17 It is the in vitro cutting efficiency of the hAce2-tdTomato model sgRNA according to the example of the present application.
[0053] Fig.18 This is a plasmid map of the hAce2-tdTomato model donor according to an embodiment of the present application.
[0054] Fig.19 The hAce2-tdTomato model primer design and gene identification results according to the examples of the present application.
[0055] Fig. 20 This is a result diagram of the gain and loss of positions at both ends of the hAce2-tdTomato model knock-in fragment according to an embodiment of the present application.
[0056] Fig.21 This is a diagram showing the verification results of the hAce2-tdTomato model immunoblotting experiment according to the example of the present application.
[0057] Fig. 22 This is a graph showing the sgRNA efficiency verification results for the Chd8 gene knockout ferret model according to an embodiment of the present application.
[0058] Fig.23 This is a diagram of the gene identification results of the Chd8 knockout ferret model according to the examples of the present application.
[0059] Fig.24 This is a diagram showing the verification results of the immunoblotting experiment in the Chd8 knockout ferret model according to the example of the present application. DETAILED DESCRIPTION
[0060] The embodiments of the present invention are described in detail below. The embodiments described below are exemplary and are only used to explain the present invention, and should not be understood as limiting the present invention.
[0061] It should be noted that the terms "first" and "second" are used for descriptive purposes only and should not be understood as indicating or implying relative importance or implicitly indicating the number of the indicated technical features. Therefore, the features defined as "first" and "second" may explicitly or implicitly include one or more of the features. Further, in the description of the present invention, unless otherwise specified, the meaning of "plurality" is two or more.
[0062] In this document, the terms “contain”, “include” or “comprise” are open expressions, that is, they include the contents specified in the present invention but do not exclude other contents.
[0063] As used herein, the terms "optionally", "optional" or "optionally" generally mean that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.
[0064] In this article, the term "insertion" refers to a term in genetics that is often used to describe small insertions or deletions (InDels) in a DNA sequence. An insertion refers to the addition of one or more nucleotides to a DNA sequence; a deletion refers to the loss of one or more nucleotides to a DNA sequence. When these insertions or deletions occur, they can change the reading frame of the DNA, resulting in changes in the sequence of the encoded protein, which may affect the function of the protein or even cause the protein to lose its function completely. This phenomenon is called a "frame-shift mutation" in genetics.
[0065] In this article, the term "Non-Homologous End Joining (NHEJ)" refers to a major mechanism for cells to repair DNA when double-strand breaks (DSBs) occur. Unlike homologous recombination repair (HDR), which requires the participation of homologous sequences, NHEJ does not rely on homologous DNA templates to repair broken DNA ends.
[0066] The present invention proposes a method for constructing a transgenic Anglo ferret model, a transgenic ferret model and sgRNA, which will be described in detail below.
[0067] Method for constructing the Anglo ferret model
[0068] In the first aspect of the present invention, the present invention proposes a method for constructing a transgenic Anglo ferret model. According to an embodiment of the present invention, the method includes: introducing sgRNA into an Anglo ferret fertilized egg to obtain a transgenic ferret model, and the sgRNA is suitable for targeting pre-intervention genes. According to the method of an embodiment of the present invention, a transgenic Anglo ferret model can be efficiently constructed, including gene knock-in, gene knockout and humanized ferret model.
[0069] According to an embodiment of the present invention, before the introduction, the method further includes: centrifuging the ferret fertilized eggs.
[0070] According to an embodiment of the present invention, the speed of the centrifugal treatment is 7800g-8000g, for example, it can be 7800g, 7810g, 7820g, 7830g, 7840g, 7850g, 7870g, 7900g, 7930g, 7950g, 7960g, 7970g, 7980g, 7990g, 8000g and the range values 7800-7990g, 7800-7980g, 7800-7970g, 7800-7960g and 7800-7950g. According to the method of the embodiment of the present invention, the moderate centrifugal treatment speed can improve the quality and survival rate of fertilized eggs, and more than 70% of the fertilized eggs show pronuclei, thereby efficiently constructing a transgenic Angora ferret model.
[0071] According to an embodiment of the present invention, the time of the centrifugation is 6 minutes to 8 minutes, for example, it can be 6 minutes, 6.1 minutes, 6.2 minutes, 6.3 minutes, 6.4 minutes, 6.5 minutes, 6.6 minutes, 6.7 minutes, 6.8 minutes, 6.9 minutes, 7 minutes, 7.1 minutes, 7.2 minutes, 7.3 minutes, 7.4 minutes, 7.5 minutes, 7.6 minutes, 7.7 minutes, 7.8 minutes, 7.9 minutes, 8 minutes and the range values 6 to 7.9 minutes, 6 to 7.8 minutes, 6 to 7.7 minutes, 6 to 7.6 minutes and 6 to 7.5 minutes. According to the method of an embodiment of the present invention, moderate centrifugation time can improve the quality and survival rate of fertilized eggs, and more than 70% of fertilized eggs show pronuclei, thereby efficiently constructing a transgenic Angora ferret model.
[0072] According to an embodiment of the present invention, the speed of the centrifugal treatment is 7850g-7950g, for example, it can be 7850g, 7860g, 7870g, 7880g, 7890g, 7900g, 7910g, 7920g, 7930g, 7940g, 7950g and the range values 7850-7940g, 7850-7930g, 7850-7920g, 7850-7910g and 7850-7900g. According to the method of the embodiment of the present invention, the moderate centrifugal treatment speed will further improve the quality and survival rate of fertilized eggs, and more than 70% of the fertilized eggs show pronuclei, thereby further efficiently constructing a transgenic Angora ferret model.
[0073] According to an embodiment of the present invention, the time of the centrifugation is 6.5 minutes to 7.5 minutes, for example, it can be 6.5 minutes, 6.6 minutes, 6.7 minutes, 6.8 minutes, 6.9 minutes, 7.0 minutes, 7.1 minutes, 7.2 minutes, 7.3 minutes, 7.4 minutes, 7.5 minutes and the range values therebetween 6.5 to 7.4 minutes, 6.5 to 7.3 minutes, 6.5 to 7.2 minutes, 6.5 to 7.1 minutes and 6.5 to 7.0 minutes. According to the method of an embodiment of the present invention, the moderate centrifugation time can further improve the quality and survival rate of fertilized eggs, and more than 70% of the fertilized eggs show pronuclei, thereby further efficiently constructing a transgenic Angora ferret model.
[0074] According to an embodiment of the present invention, the centrifugal speed is 7900g and the centrifugal time is 7 minutes. According to the method of the embodiment of the present invention, the moderate centrifugal speed and centrifugal time will further improve the quality and survival rate of fertilized eggs, and more than 70% of the fertilized eggs show pronuclei, thereby further efficiently constructing a transgenic Angora ferret model.
[0075] According to an embodiment of the present invention, the introduction of sgRNA into the fertilized egg of Anglo ferret is performed by at least one of the following methods: nuclear microinjection and cytoplasmic microinjection.
[0076] According to an embodiment of the present invention, after the centrifugation treatment, the cell nucleus microinjection is performed on the fertilized egg showing the nuclear region.
[0077] According to an embodiment of the present invention, after the centrifugation, the fertilized egg that does not show a nuclear region is subjected to the cytoplasmic microinjection.
[0078] According to an embodiment of the present invention, the cell nucleus microinjection pressure is 200Pa-240Pa, for example, it can be 200Pa, 205Pa, 210Pa, 215Pa, 220Pa, 225Pa, 230Pa, 231Pa, 232Pa, 233Pa, 234Pa, 235Pa, 236Pa, 237Pa, 238Pa, 239Pa, 240Pa and ranges therebetween of 200Pa-240Pa, 200-239Pa, 200-238Pa, 200-237Pa, 200-236Pa and 200-235Pa. According to the method of the embodiment of the present invention, a transgenic Angora ferret model can be further efficiently constructed.
[0079] According to an embodiment of the present invention, the nuclear microinjection time is 0.35 seconds to 0.45 seconds, for example, it can be 0.35 seconds, 0.36 seconds, 0.37 seconds, 0.38 seconds, 0.39 seconds, 0.40 seconds, 0.41 seconds, 0.42 seconds, 0.43 seconds, 0.44 seconds, 0.45 seconds and the range values therebetween 0.35 to 0.44 seconds, 0.35 to 0.43 seconds, 0.35 to 0.42 seconds, 0.35 to 0.41 seconds and 0.35 to 0.40 seconds. According to the method of the embodiment of the present invention, a transgenic Angora ferret model can be further efficiently constructed.
[0080] According to an embodiment of the present invention, the cytoplasmic microinjection pressure is 190Pa-210Pa, for example, it can be 190Pa, 191Pa, 192Pa, 193Pa, 194Pa, 195Pa, 196Pa, 197Pa, 198Pa, 199Pa, 200Pa, 201Pa, 202Pa, 203Pa, 204Pa, 205Pa, 206Pa, 207Pa, 208Pa, 209Pa, 210Pa and ranges therebetween of 190-209Pa, 190-208Pa, 190-207Pa, 190-206Pa, 190-205Pa and 190-204Pa. According to the method of the embodiment of the present invention, a transgenic Angora ferret model can be further efficiently constructed.
[0081] According to an embodiment of the present invention, the time of the cytoplasmic microinjection is 0.25 seconds to 0.35 seconds, for example, it can be 0.25 seconds, 0.26 seconds, 0.27 seconds, 0.28 seconds, 0.29 seconds, 0.30 seconds, 0.31 seconds, 0.32 seconds, 0.33 seconds, 0.34 seconds, 0.35 seconds and the range values therebetween 0.25 to 0.34 seconds, 0.25 to 0.33 seconds, 0.25 to 0.32 seconds, 0.25 to 0.31 seconds and 0.25 to 0.30 seconds. According to the method of the embodiment of the present invention, a transgenic Angora ferret model can be further efficiently constructed.
[0082] According to an embodiment of the present invention, the ferret fertilized egg is obtained by the following method:
[0083] HCG is injected into the body of a female mink after normal mating; and a fertilized egg is removed after a predetermined time of HCG injection to obtain the ferret fertilized egg; wherein the HCG is injected into the body of a female mink within 30 minutes to 1 hour after normal mating.
[0084] According to an embodiment of the present invention, the injection amount of HCG is 250 units to 350 units.
[0085] According to an embodiment of the present invention, the fertilized egg retrieval process is performed 42 to 44 hours after the HCG injection.
[0086] According to an embodiment of the present invention, the sgRNA is suitable for targeting at least one of Emx1, Nkx2.1, hAce2 and Chd8.
[0087] According to an embodiment of the present invention, the CrRNA of the sgRNA has at least one of the nucleotide sequences shown in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 44.
[0088] According to an embodiment of the present invention, the CrRNA of the sgRNA has a nucleotide sequence as shown in SEQ ID NO:1.
[0089] According to an embodiment of the present invention, the CrRNA of the sgRNA has a nucleotide sequence as shown in SEQ ID NO:2.
[0090] According to an embodiment of the present invention, the CrRNA of the sgRNA has a nucleotide sequence as shown in SEQ ID NO:3.
[0091] According to an embodiment of the present invention, the CrRNA of the sgRNA has a nucleotide sequence as shown in SEQ ID NO:44.
[0092] Transgenic Anglo Ferret Model
[0093] In a second aspect of the present invention, the present invention provides a transgenic Anglo ferret model. According to an embodiment of the present invention, the model is prepared using the method described in the first aspect of the present invention. The ferret model according to an embodiment of the present invention can be widely used in the study of cerebral cortex development and function, autism mechanism research, and the pathogenic mechanism of SARS-CoV-2 infection and vaccine drug development.
[0094] According to an embodiment of the present invention, the transgenic Anglo ferret model includes at least one of Emx1-CreERT2 transgenic Anglo ferret, Nkx2.1-CreERT2 transgenic Anglo ferret, humanized Ace2 replacement ferret model and Chd8 knockout transgenic Anglo ferret.
[0095] sgRNA
[0096] In the third aspect of the present invention, the present invention proposes an sgRNA. According to an embodiment of the present invention, the CrRNA of the sgRNA has at least one of the nucleotide sequences shown in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:44. According to an embodiment of the present invention, the CrRNA of the sgRNA has a nucleotide sequence as shown in SEQ ID NO:1. According to an embodiment of the present invention, the CrRNA of the sgRNA has a nucleotide sequence as shown in SEQ ID NO:2. According to an embodiment of the present invention, the CrRNA of the sgRNA has a nucleotide sequence as shown in SEQ ID NO:3. According to an embodiment of the present invention, the CrRNA of the sgRNA has a nucleotide sequence as shown in SEQ ID NO:44. The sgRNA according to an embodiment of the present invention can accurately and efficiently target pre-intervention genes.
[0097] It should be explained that the sgRNA in the present application is a complex sequence formed by the connection of crRNA and trRNA.
[0098] According to an optional embodiment of the present invention, the trRNA sequence is as follows: GGAACCATTCAAAACAGCATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGC ACCGAGTCGGTGC (SEQ ID NO: 45).
[0099] The sequence of the present invention is shown in the following table
[0100] Sequence Listing
[0101]
[0102]
[0103] The scheme of the present invention will be explained below in conjunction with the embodiments. It will be appreciated by those skilled in the art that the following embodiments are only used to illustrate the present invention and should not be considered as limiting the scope of the present invention. Where specific techniques or conditions are not indicated in the embodiments, the techniques or conditions described in the literature in this area or the product specifications are used. The reagents or instruments used are not indicated by the manufacturer and are all conventional products that can be obtained commercially.
[0104] Embodiment 1:
[0105] In this example, the Emx1-CreERT2 ferret model was constructed. The plasmid (Emx1-IRES-CreERT2) of the Emx1-CreERT2 ferret model was designed as follows: Figure 1As shown, in this embodiment, an exogenous DNA fragment with IRES-CreERT2 is inserted between the end of the fourth exon of the ferret Emx1 gene and the 3'UTR region to achieve the expression of Cre recombinase (CreER protein) fused with estrogen receptor in cells specifically expressing the Emx1 gene. Under the induction of Tamoxifen (TM for short), CreER enters the cell nucleus and exerts the effect of Cre recombinase. The specific experimental process of this embodiment is as follows:
[0106] 1. Gene Targeting Design
[0107] The ferret genome sequence of the corresponding gene was downloaded from the NCBI and Ensembl websites, and the sequence was completed by cloning the wild-type ferret genome, and then the targeting sites were designed for different strains.
[0108] Appropriate sgRNA sites were selected according to the requirements of different strains and the specific conditions of different genes. For example, in strains with Emx1 gene knock-in, the target site was designed at the end of the fourth exon of the Emx1 gene.
[0109] 2. sgRNA site design
[0110] After determining the target site, select the specific target site and sgRNA sequence on the shared resource websites such as CRISPOR and CHOPCHOP. Taking the CRISPOR website as an example, in the sgRNA (composed of CrRNA and TrRNA) design software of the website, select the species as ferret to select approximately 100bp sequences upstream and downstream of the knock-in site for design. After calculation, the website will give all possible CrRNA information of the current sequence, including specific location, off-target possibility, and prediction of in vitro and in vivo enzyme cutting efficiency. Then use the BLAST software on the NCBI website to confirm whether there is a problem with the target, and then comprehensively consider and select 4 CrRNA sequences close to the target site, with high sequence specificity, high in vitro and in vivo enzyme cutting efficiency, and appropriate GC content as candidate CrRNAs, and then synthesize them for the next step of screening. The designed CrRNA sequences of the Emx1 gene are: Emx1-CrRNA-1 (the specific nucleotide sequence is shown in SEQ ID NO: 4), Emx1-CrRNA-2 (the specific nucleotide sequence is shown in SEQ ID NO: 1), Emx1-CrRNA-3 (the specific nucleotide sequence is shown in SEQ ID NO: 5), and Emx1-CrRNA-4 (the specific nucleotide sequence is shown in SEQ ID NO: 6).
[0111] 3. sgRNA cutting efficiency test in vitro
[0112] After the sgRNA is designed, the corresponding CrRNA and TrRNA are ordered from IDT, and then the RNA powder is dissolved according to the specified concentration to obtain the corresponding solution. Taking the Emx1 gene locus as an example, the method for other gene loci is similar.
[0113] 1)Reference Figure 2 , clone the sequences before and after the sgRNA targeting site from the wild-type ferret genome;
[0114] Design primer Ex11Fw1: 5'-ATGCAATGGCTTTTTATACATTCGCCT-3' (SEQ ID NO: 7)
[0115] Ex11Re1:5'-TAGAGCTGGAGTTCAGGATCAGGG-3'(SEQ ID NO:8)
[0116] Configure the PCR reaction system as shown in Table 1: 50 μL per reaction, 8 reactions in total
[0117] Table 1: PCR reaction system
[0118] Reagents volume <![CDATA[Water (H2O)]]> 19μL 10μM Ex11Fw1 2.5μL 10μM Ex11Re1 2.5μL Q5 2x master mix 25μL Ferret genomic DNA 1.0μL Total reaction volume 50μL
[0119] 95℃2min, 35x(95℃30s, 50℃30s, 68℃40s), 68℃15min, 10℃hold
[0120] Gel recovery of target DNA fragments.
[0121] 2) preparing an in vitro sgRNA reaction system as shown in Table 2;
[0122] Table 2: In vitro sgRNA reaction system
[0123]
[0124] After the preparation is completed, mix carefully, centrifuge slightly, and place in a PCR instrument for reaction at 37℃ for 2-4 hours.
[0125] 3) Run the gel, image, analyze the grayscale values of the cleaved product fragments and the remaining fragments of the template DNA, and obtain the optimal targeting sequence.
[0126] All four sgRNAs can cleave the 1173bp Emx1 DNA template into 598bp and 575bp fragments. Figure 3 As can be seen in the figure, Emx1-CrRNA-2 (corresponding to Figure 3 The in vitro cleavage efficiency of the third lane in the experiment was the highest, so the genomic site targeted by Emx1-CrRNA-2 was selected as the target for subsequent injection in this application.
[0127] 4. Donor Plasmid Construction
[0128] Homology-Directed Repair (HDR) was used to insert the exogenous fragment IRES-CreERT2 at the end of the Emx1 gene. Figure 4 The endogenous sequences of the target upstream and downstream Emx1 gene were added to both ends of the insertion sequence, and the plasmid was verified by Sanger sequencing after assembly.
[0129] 5. Embryo Microinjection
[0130] After preparing sgRNA and donor plasmid, a total of 9 microinjection experiments were performed, and the specific data are shown in Table 3 below. A total of 36 successfully mated donor female minks were used to construct the Emx1-CreERT2 snow ferret model, and 308 fertilized eggs were obtained. 179 of the 308 fertilized eggs were observed to have pronuclei under a microscope after centrifugation, and pronuclear injection was performed; another 129 fertilized eggs could not be observed in the nuclear area under the microscope after centrifugation, and cytoplasmic injection was performed. After injection, a total of 153 fertilized eggs survived, with a survival rate of 49.7%. 153 fertilized eggs were transplanted into the oviducts of 17 recipient female minks, and a total of 55 pups were produced. A total of 6 positive F0 individuals were obtained, with a positive rate of 10.9% for F0 pups, and a total success rate of 1.9%. Individuals of the positive Emx1-CreERT2 ferret model have no significant differences from negative individuals in the same litter and from wild-type individuals, and can mate and reproduce with wild-type ferrets to obtain F1 offspring of this strain.
[0131] Table 3: Data related to the preparation of Emx1-CreERT2 ferret strain
[0132]
[0133] 6. Genotype identification and sequencing verification
[0134] For newborn pups, tail tissue was taken for genotyping. To detect whether there was random insertion and random shearing of the inserted fragment, refer to Figure 5, the present application respectively designs three pairs of different primers LA, R and IN at the junction of the exogenous gene and the endogenous gene, and inside the exogenous gene: Emx1-LA-F1 (SEQ ID NO: 18), Emx1-LA-R1 (SEQ ID NO: 19), Emx1-R-F3 (SEQ ID NO: 20), Emx1-R-R3 (SEQ ID NO: 21), Emx1-IN-F2 (SEQ ID NO: 22), Emx1-IN-R2 (SEQ ID NO: 23), and the sizes of the positive bands amplified by primers LA, R and IN are 1294bp, 946bp, and 361bp, respectively. Among them, primers LA and R are used to detect whether random insertion occurs, and primer IN is used to detect whether the inserted fragment is complete. Among the five samples tested in the present application, only the three pairs of primers of samples No. 2 and No. 3 have positive bands, so No. 2 and No. 3 are positive animals of the Emx1-CreERT2 strain. Sample No. 1 had only a positive band with the IN primer, and both LA and R had negative bands, which might be a chimeric insertion or a random insertion, so it was eliminated.
[0135] After PCR identification, the present application designs longLA and longR primers at both ends of the plasmid insertion site: Emx1-longLA-F2 (SEQ ID NO: 24), Emx1-longLA-R2 (SEQ ID NO: 25), Emx1-longR-F1 (SEQ ID NO: 26) and Emx1-longR-R1 (SEQ ID NO: 27), and further detects whether the exogenous gene is accurately inserted at the insertion site by genome sequencing of the positive individuals identified by the PCR method. The present application is exemplified by No. 2 positive ferrets, reference Figure 6 The sequencing results showed that no additional insertions or deletions occurred at both ends of the insertion site.
[0136] 7. Functional Verification
[0137] In this example, cells expressing fluorescent proteins were co-stained with cell-specific protein markers to analyze the cell types. Emx1-CreERT2 positive pups at 8 days after birth were stereotaxically injected with rAAV-hSyn-DIO-mCherry-WPRE virus (containing Loxp-Stop-Loxp sequence) in the cerebral cortex, and high concentrations of tamoxifen (TM) were injected four times from P10 to P15, with a concentration of 20 mg / kg. Figure 7, perfusion, sampling, slicing and staining were performed at P39. The AAV viral promoter used in this embodiment is hSyn, which is only expressed in neurons, so only neurons express the red fluorescent protein mCherry, and astrocytes and oligodendrocytes do not express mCherry. And mCherry-positive cells co-localize with the specific marker of cortical excitatory neurons, the sample homeobox 1 (CUX1), and mCherry-positive cells co-localize with the specific marker of neuronal nuclei (NEUN); mCherry-positive cells do not co-localize with parvalbumin (PV) inhibitory neurons, do not co-localize with the marker of astrocytes, the glial fibrillary acid protein (GFAP), do not co-localize with the marker of oligodendrocytes, the oligodendrocyte transcription factor OLIG2, and do not co-localize with the marker of microglia / macrophages, the ionized calcium binding adapter molecule 1 (IBA1). In mice, PV neurons account for about 40% of the total inhibitory neurons in the cerebral cortex, and are the type of neurons with the largest number of cells in inhibitory neurons. Therefore, this example verifies the specific expression of CreER protein and the function of recombinase in the Emx1-CreERT2 model in vivo. The scheme of this example successfully constructed the Emx1-CreERT2 transgenic Anglo ferret model.
[0138] Example 2
[0139] The experimental process of this example is basically the same as that of Example 1, except that in this example, the Nkx2.1-CreERT2 ferret strain was constructed to achieve specific labeling of inhibitory neurons originating from MGE and PoA in the ferret brain. The knock-in plasmid (Nkx2.1-IRES-CreERT2) of the Nkx2.1-CreERT2 ferret model was designed as follows: Figure 8 As shown, a knock-in site was designed between the end of the second exon of the Nkx2.1 gene and the 3'UTR, and an IRES-CreERT2 gene fragment was inserted.
[0140] 1.Reference Fig. 9 , the sequences before and after the sgRNA targeting site of Nkx2.1 were cloned from the wild-type ferret genome;
[0141] Design primer NKX2-1 Fw1: 5'-CAAGCAACAGAAGTACCTGTCGG-3' (SEQ ID NO: 14)
[0142] NKX2-1 Re1:5'-TAGAGTCCAGAGCCGCGT-3'(SEQ ID NO:15)
[0143] In this example, four sgRNAs that meet the requirements are designed at the end of the second exon of the Nkx2.1 gene: Nkx2.1-CrRNA-1 (the specific nucleotide sequence is shown in SEQ ID NO: 9), Nkx2.1-CrRNA-2 (the specific nucleotide sequence is shown in SEQ ID NO: 10), Nkx2.1-CrRNA-3 (the specific nucleotide sequence is shown in SEQ ID NO: 2) and Nkx2.1-CrRNA-4 (the specific nucleotide sequence is shown in SEQ ID NO: 11), and the designed target sites are used in vitro to verify the in vitro cleavage efficiency. Results reference Fig.10 The results showed that all four sgRNAs cut the 988bp template into different sizes. Moreover, under the same loading amount, by comparing the gray values of the bands, it was found that Nkx2.1-CrRNA-3 (corresponding to the #3sgRNA in the fourth lane in the figure) had the best cutting effect, so the site targeted by Nkx2.1-CrRNA-3 in the genome was selected as the target for subsequent injection.
[0144] 2. During the construction of the donor plasmid, the exogenous fragment IRES-CreERT2 was inserted into the end of the Nkx2.1 gene using the HDR method. It was necessary to design upstream and downstream endogenous sequences as homology arms at both ends of the exogenous insertion fragment, combine the selected sgRNA and knock-in design, assemble the donor plasmid, and finally verify it through Sanger sequencing. Fig.11 shown.
[0145] 3. After preparing the sgRNA and donor plasmid fragments, this embodiment completed a total of three microinjection experiments of the Nkx2.1-CreERT2 model. This embodiment exemplifies the results of a microinjection experiment, and the specific data are shown in Table 4 below. A total of 8 donor female minks were used in the microinjection experiment, and 83 fertilized eggs were obtained. After centrifugation, the pronuclei of the 83 fertilized eggs were observed under a microscope, and pronuclear injection was performed. After injection, a total of 43 fertilized eggs survived, with a survival rate of 51.8%. The 43 fertilized eggs were transplanted into the oviducts of 4 recipient female minks, and a total of 22 pups were produced, 2 positive F0 individuals were obtained, and the F0 positive rate was 9.1%, with a total success rate of 2.4%. The surviving positive individuals were not significantly different from wild-type individuals, and could mate with wild-type ferrets to breed the F1 offspring of the strain.
[0146] Table 4: Data related to the preparation of Nkx2.1-CreERT2 ferret strain
[0147]
[0148] 4. In order to confirm the genotype of the newborn ferrets of the Nkx2.1-CreERT2 strain, the tail tissue was taken for gene identification. In this example, two pairs of primers L and R were designed at the junction of the exogenous gene of the strain and the endogenous gene fragment of the ferret: Nkx2.1-LF (SEQ ID NO: 28), Nkx2.1-LR (SEQ ID NO: 29), Nkx2.1-RF (SEQ ID NO: 30), and Nkx2.1-RR (SEQ ID NO: 31) for genotype identification. Fig.12 , the products amplified by the two pairs of primers were 543bp and 665bp respectively. No. 1 is a plasmid positive control. Samples 2 and 6 both produced products of 543bp and 665bp after amplification by the two pairs of primers, indicating that samples 2 and 6 are genotype positive animals. Samples 3, 4, 5 and 7 have no positive bands, indicating that they are genotype negative animals.
[0149] 5. After the genotype is determined, in order to verify the accuracy of the gene knock-in, this example uses IN primers Nkx2.1-IN-F (SEQ ID NO: 32) and Nkx2.1-IN-R (SEQ ID NO: 33) to perform PCR amplification on the genomic fragments at the junction of the upstream and downstream homologous arms of the insertion site and the endogenous gene of the positive individual, and amplify the corresponding fragments for Sanger sequencing. Taking individual No. 6 as an example, reference Fig.13 The sequencing results showed that there were no additional insertions or deletions at the junction of the exogenous gene and the endogenous gene.
[0150] 6. In this example, the dorsal cortex, medial ganglionic eminence (MGE) region and kidney tissues of Nkx2.1-CreERT2 positive and negative animals on the 31st day of pregnancy (E31) were respectively taken for immunofluorescence blotting (western blot) experimental verification. At this time, there were a large number of neural precursor cells and newborn neurons in both the dorsal and ventral sides of the telencephalon. In addition, astrocytes of Aldh1l1-CreERT2 mice were isolated in this example as a positive control for Cre protein. The results showed that, with reference to Fig.14 The Cre protein was expressed in both the dorsal and ventral MGE of the telencephalon of Nkx2.1-CreERT2 embryos, indicating that the scheme of this example successfully constructed the Nkx2.1-CreERT2 transgenic Anglo ferret model. The other processes were the same as those in Example 1.
[0151] Example 3
[0152] The experimental process of this example is basically the same as that of Example 1, except that in this example, the humanized Ace2 gene is precisely knocked into the endogenous Ace2 gene of the ferret to replace the expression of the endogenous Ace2 of the ferret, simulate the environment in which the humanized Ace2 is expressed in the ferret, and enhance the susceptibility of the ferret to the new coronavirus. The design schematic diagram of the humanized Ace2 knock-in plasmid (fAce2-hAce2-IRES-tdTomato-WPRE-pA) is shown in the figure. Fig.15 shown.
[0153] 1.Reference Fig.16 , the sequences before and after the sgRNA targeting site of Ace2 were cloned from the wild-type ferret genome;
[0154] Design primer Ace2 Fw1: 5'-AAGTACCACTACTACCCCCGT-3' (SEQ ID NO: 16)
[0155] Ace2 Re1:5'-ACCCCTACATAGCCACGGAA-3'(SEQ ID NO:17)
[0156] In this example, for the humanized Ace2 model, three sgRNAs hAce2-CrRNA-1 (SEQ ID NO: 12), hAce2-CrRNA-2 (SEQ ID NO: 3) and hAce2-CrRNA-3 (SEQ ID NO: 13) were designed in the second exon of the ferret Ace2 gene, and the cleavage efficiency was tested in vitro. The results are as follows Fig.17 As shown in the figure, under the same loading amount, the three sgRNAs will cut the 595bp template into different sizes. According to the gray value analysis of different bands, hAce2-CrRNA-2 (corresponding to Fig.17 The cutting efficiency of the fourth lane from left to right in the figure is the best, so the present application selects the genomic site targeted by hAce2-CrRNA-2 as the target for subsequent injection.
[0157] 2. When constructing the humanized Ace2 model donor plasmid, this example added the upstream and downstream endogenous gene fragments of the target as the left and right homology arms to the fragments at both ends of the insertion sequence hAce2-IRES-tdTomato-WPRE-pA to obtain the final humanized hAce2 model donor plasmid. After the plasmid was successfully constructed, Sanger sequencing was performed, and the final confirmed knock-in plasmid map was as follows Fig.18 shown.
[0158] 3. After obtaining sgRNA and donor plasmid fragments, this embodiment completed a total of 11 microinjection experiments of the humanized Ace2 model, and the specific data are shown in Table 5 below. A total of 39 donor female minks were used to construct the humanized Ace2 model, and 386 fertilized eggs were obtained. After centrifugation, 275 fertilized eggs were observed under a microscope for pronuclear injection; another 111 eggs could not observe the nuclear area after centrifugation, and cytoplasmic injection was performed. After injection, a total of 212 fertilized eggs survived, with a survival rate of 54.9%. 212 fertilized eggs were transplanted into the oviducts of 22 recipient female minks, and a total of 79 pups were produced, 10 positive F0 individuals were obtained, the F0 positive rate was 12.7%, and the total success rate was 2.6%. There is no significant difference between the positive individuals and the wild-type individuals, and they can mate with wild-type ferrets to breed the F1 offspring population of this strain.
[0159] Table 5: Data related to the preparation of humanized Ace2 ferret strain
[0160]
[0161] 4. In order to determine the genotype of newborn ferrets, tail tissues were taken for gene identification. In this example, three pairs of primers L, R, and IN were designed at the junction of the exogenous inserted gene fragment and the ferret endogenous gene fragment and inside the inserted fragment: Ace2-L1F (SEQ ID NO: 34), Ace2-L1R (SEQ ID NO: 35), Ace2-R-3F (SEQ ID NO: 36), Ace2-R-3R (SEQ ID NO: 37), Ace2-IN-3F (SEQ ID NO: 38), and Ace2-IN-3R (SEQ ID NO: 39). PCR was used for identification. The primer design and identification results are shown in FIG. Fig.19 As shown. By comparing the PCR result bands, the sizes of the positive bands amplified by the three pairs of primers L, R, and IN were 994bp, 564bp, and 511bp, respectively. The positive control P is a donor plasmid fragment. By comparison, it was found that the PCR results of the three pairs of primers of individuals No. 5 and No. 6 all showed bands of the same size as the positive control, so this example considered that 5 and 6 were positive samples, and the rest were negative samples.
[0162] 5. For the positives identified by the genome, in order to further confirm the accuracy of the insertion, in this example, primers LA and RA were designed at both ends of the knock-in site: Ace2-LA-F3 (SEQ ID NO: 40), Ace2-LA-R3 (SEQ ID NO: 41), Ace2-RA-F2 (SEQ ID NO: 42) and Ace2-RA-R2 (SEQ ID NO: 43), and Sanger sequencing was performed on the junction of the homologous arms of the inserted sequence and the endogenous gene fragment. Taking positive No. 6 as an example, reference Fig. 20 , sequencing did not reveal any additional insertions or deletions at the knock-in site, and the remaining positive individuals were also sequenced and verified using the same method.
[0163] 6. In this example, the expression of human Ace2 protein was verified at the protein expression level. After extracting protein samples from different organs and tissues of positive animals and wild-type animals, such as lung, kidney, large intestine, small intestine, etc., western blotting was performed to characterize the hybridization results of the inserted sequence protein expression using tdTomato protein expression. The results are as follows: Fig.21 As shown, compared with the wild type, the humanized model has tdTomato expression in the small intestine, large intestine and kidney, which shows that the scheme of this example successfully constructed the hAce2-tdTomato transgenic Anglo ferret model. The other processes are the same as in Example 1.
[0164] Example 4
[0165] Autism spectrum disorder (ASD) is a neurological disease with a high incidence rate. There are multiple genetic factors controlling mechanisms. Among the cases where single gene mutations cause diseases, the frequency and risk factor of Chd8 gene mutations are the highest. The experimental process of this embodiment is substantially the same as that of Example 1, except that the transgenic preparation system established in this embodiment is used to construct a Chd8 gene knockout model. Using the method of non-homologous end joining (NHEJ), sgRNA is used to target genomic sites, so that Cas9 protein is bound to a specific sequence of the genome, and cutting is performed, which eventually leads to gain and loss positions at the recognition site, and the expression of Chd8 protein is disordered in the form of frameshift mutations, thereby achieving the effect of knockout. This implementation targets the second exon of the Chd8 gene, knocks out or inserts non-3N bases, changes the translation order of subsequent amino acids, thereby changing its original expression sequence, and achieving the purpose of knockout. The conservative sequence selected for the crRNA site is CAATGGAAACACCTGGTCGAAGG (SEQ ID NO: 44). It has been verified that at this sgRNA site, Cas9 can cut the 371bp template DNA fragment into 254bp and 117bp bands, and the target cutting efficiency is high. Therefore, the genomic site targeted by this sgRNA is selected as the target for the subsequent preparation of the knockout model. Fig. 22 .
[0166] After confirming sgRNA, this embodiment completed a total of 7 injection experiments of the Chd8 gene, and the specific data are shown in Table 6 below. A total of 18 donor female minks were used to construct the Chd8 knockout model, and 163 fertilized eggs were obtained. After centrifugation, 116 fertilized eggs were observed under a microscope for pronuclear injection; another 47 eggs could not be observed in the nuclear area after centrifugation, and cytoplasmic injection was performed. After injection, a total of 98 fertilized eggs survived, with a survival rate of 56.4%. 98 fertilized eggs were transplanted into the oviducts of 11 recipient female minks, and a total of 38 pups were produced, and 13 effectively edited positive F0 individuals were obtained. The F0 positive rate was 34.2%, and the total success rate was 8%. The positive animals obtained were not significantly different from wild-type animals, and the positive snow ferrets were no different from wild-type animals in terms of exercise, weight, diet, etc., and could mate with wild-type animals to breed the F1 offspring population of this strain.
[0167] Table 6: Data related to the preparation of Chd8 knockout strains
[0168]
[0169] In order to confirm the genotype of newborn ferrets, it is necessary to cut part of the tail tissue of the young ferret, extract genomic DNA, amplify the genomic DNA fragment of about 700 bp before and after the sgRNA targeting site, and then cut and purify it. Then, the purified PCR results are introduced into competent bacteria by Top-clone method, and then the monoclonal strain is selected for Sanger sequencing to analyze the gain and loss of the target site. Fig.23 The results showed that compared with the wild-type genome sequence, there were gains and losses of 3N and non-3N in the knockout results. In this example, only the ferrets with non-3N results in the sequencing results were retained as positive knockout ferrets to establish the strain.
[0170] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine the different embodiments or examples described in this specification and the features of the different embodiments or examples, without contradiction.
[0171] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.
Claims
1. A method for constructing a transgenic Anglo ferret model, characterized in that: include: sgRNAs suitable for targeting a pre-intervention gene were introduced into fertilized Anglo ferret eggs to obtain a transgenic ferret model.
2. The method according to claim 1, characterized in that Prior to the introduction, the method further comprises: centrifuging the ferret fertilized eggs.
3. The method according to claim 2, characterized in that The speed of the centrifugal treatment is 7800g-8000g; Optionally, the centrifugal treatment time is 6 minutes to 8 minutes; Preferably, the centrifugal treatment speed is 7850g-7950g; Preferably, the centrifugal treatment time is 6.5 minutes to 7.5 minutes.
4. The method according to claim 3, characterized in that The introduction of sgRNA into the fertilized eggs of Anglo ferrets is performed by at least one of the following methods: nuclear microinjection and cytoplasmic microinjection; Optionally, after the centrifugation, the fertilized egg showing the nuclear region is subjected to the cell nuclear microinjection; Optionally, after the centrifugation, the fertilized egg that does not show a nuclear region is subjected to the cytoplasmic microinjection.
5. The method according to claim 4, characterized in that The cell nucleus microinjection pressure is 200Pa to 240Pa; Optionally, the cell nucleus microinjection time is 0.35 seconds to 0.45 seconds; Optionally, the cytoplasmic microinjection pressure is 190Pa to 210Pa; Optionally, the time of the cytoplasmic microinjection is 0.25 seconds to 0.35 seconds.
6. The method according to claim 1, characterized in that The ferret fertilized egg is obtained by the following method: Inject HCG into female minks after normal mating; and After a predetermined time of HCG injection, a fertilized egg retrieval process is performed to obtain the ferret fertilized egg; Wherein, the HCG is injected into the body of a female mink within 30 minutes to 1 hour after normal mating; Preferably, the injection amount of HCG is 250 units to 350 units; Preferably, the fertilized egg retrieval process is performed 42 to 44 hours after HCG injection.
7. The method according to claim 1, characterized in that The sgRNA is suitable for targeting at least one of Emx1, Nkx2.1, hAce2 and Chd8; Optionally, the crRNA of the sgRNA has at least one of the nucleotide sequences shown in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO:
44.
8. A transgenic Anglo ferret model, characterized in that: The method is prepared by any one of claims 1 to 7.
9. The model according to claim 8, characterized in that The transgenic Anglo ferret model includes at least one of an Emx1-CreERT2 transgenic Anglo ferret, a Nkx2.1-CreERT2 transgenic Anglo ferret, a humanized Ace2 replacement ferret model, and a Chd8 knockout transgenic Anglo ferret.
10. A sgRNA, characterized in that The crRNA of the sgRNA has at least one of the nucleotide sequences shown in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 44.
Citation Information
Patent Citations
Method for establishing ferret model capable of applying to study human disease and application thereof
CN105210981A
Compositions and methods for enhanced genome editing
US20190010519A1
